Free shipping on all orders over $ 500

Icotinib

Cat. No. M1784

All AbMole products are for research use only, cannot be used for human consumption.

Icotinib Structure
Synonym:

BPI-2009H

Size Price Availability Quantity
10mM*1mL in DMSO USD 90 In stock
1mg USD 40 In stock
5mg USD 72 In stock
10mg USD 105 In stock
25mg USD 185 In stock
50mg USD 290 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Icotinib (BPI-2009H), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), in two EGFR-mutated lung cancer cell lines compared to A549, a cell line without EGFR mutations. Icotinib blocked EGFR-mediated intracellular tyrosine phosphorylation (IC50 = 45 nM) in the human epidermoid carcinoma A431 cell line and inhibits tumor cell proliferation.

Protocol (for reference only)
Cell Experiment
Cell lines A431 cell line
Preparation method MTT assay Cells (103/well) were seeded into 96-well plates in RPMI-1640 medium containing 10% FBS and grown in a 5% CO2 incubator at 37 ◦C. After 24 h, cells were treated with Icotinib at 0, 0.78, 1.56, 3.125, 6.25, 12.5 or 25 µM for 96 h. Cell proliferation was calculated by subtracting the mean absorbance value on day 0 from the mean absorbance value on day 4.
Concentrations 0, 0.78, 1.56, 3.125, 6.25, 12.5 or 25 µM
Incubation time 96h
Animal Experiment
Animal models mice bearing A431, A549, H460 and HCT8 tumor xenografts
Formulation 0.5% CMCNa
Dosages 30 mg/kg once a week
Administration i.p.
Chemical Information
Molecular Weight 391.4
Formula C22H21N3O4
CAS Number 610798-31-7
Solubility (25°C) DMSO ≥ 72 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Ruan CJ, et al. Eur J Clin Pharmacol. Effect of the CYP2C19 genotype on the pharmacokinetics of icotinib in healthy male volunteers.

[2] Yang G, et al. Oncol Rep. Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer.

[3] Tan F, et al. Lung Cancer. Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies.

Related EGFR/HER2 Products
AEE788

AEE788 (NVP-AEE788) is a novel multitargeted HER 1/2 and VEGFR 1/2 receptor family tyrosine kinases inhibitor with IC50 of 2, 6, 77, 59 nM for EGFR, ErbB2, KDR, and Flt-1.

Sapitinib (AZD8931)

AZD8931 (Sapitinib) is an equipotent, reversible inhibitor of Signaling by EGFR, ERBB2 (HER2), and ERBB3 with IC50 of 4, 3, 4 nM respectively.

Afatinib

Afatinib (BIBW 2992) is a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor.

CP-724714

CP-724714 is a potent and selective orally active HER-2 tyrosine kinase inhibitor, IC50 = 3 nM.

Erlotinib Hydrochloride

Erlotinib is an inhibitor of human EGFR tyrosine kinase (IC50 = 2 nM) and decreases EGFR autophosphorylation in tumor cells (IC50 = 20 nM).

  Catalog
Abmole Inhibitor Catalog




Keywords: Icotinib, BPI-2009H supplier, EGFR/HER2, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.